{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:59:55Z","timestamp":1788454795086,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID\/NIH R21","doi-asserted-by":"publisher","award":["R21AI101685"],"award-info":[{"award-number":["R21AI101685"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32AI95190"],"award-info":[{"award-number":["T32AI95190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune\/University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.101","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T22:41:59Z","timestamp":1527806519000},"page":"4023-4031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model"],"prefix":"10.1016","volume":"36","author":[{"given":"Kelsey A.","family":"Gregg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Harberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Cayatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.101_b0005","first-page":"1055","article-title":"Global routine vaccination coverage, 2013","volume":"63","author":"Harris","year":"2014","journal-title":"MMWR Morbidity Mortality Weekly Rep"},{"key":"10.1016\/j.vaccine.2018.05.101_b0010","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Mortality","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.101_b0015","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.vaccine.2008.02.063","article-title":"Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection","volume":"26","author":"Bungener","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0020","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0025","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.05.101_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"Martin","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.05.101_b0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/bcmd.1998.0201","article-title":"Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region","volume":"24","author":"Poltorak","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.vaccine.2018.05.101_b0040","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.bbalip.2017.01.004","article-title":"Lipid A structural modifications in extreme conditions and identification of unique modifying enzymes to define the Toll-like receptor 4 structure-activity relationship","volume":"1862","author":"Scott","year":"2017","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.vaccine.2018.05.101_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cyto.2015.03.001","article-title":"Space and time: New considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs)","volume":"74","author":"Perkins","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0050","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1073\/pnas.1424980112","article-title":"CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance","volume":"112","author":"Rajaiah","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2018.05.101_b0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.101_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00492-17","article-title":"Rationally designed TLR4 ligands for vaccine adjuvant discovery","volume":"8","author":"Gregg","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2018.05.101_b0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1469-0691.12540","article-title":"Plague history: Yersin's discovery of the causative bacterium in 1894 enabled, in the subsequent century, scientific progress in understanding the disease and the development of treatments and vaccines","volume":"20","author":"Butler","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.101_b0070","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1128\/JB.188.4.1381-1388.2006","article-title":"Characterization of late acyltransferase genes of Yersinia pestis and their role in temperature-dependent lipid A variation","volume":"188","author":"Rebeil","year":"2006","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mi.2009.131","article-title":"Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection","volume":"3","author":"Ramirez","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0080","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.4049\/jimmunol.182.2.1211","article-title":"Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost","volume":"182","author":"Ramirez","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","article-title":"Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines","volume":"26","author":"Miura","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Muench","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0095","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1128\/IAI.70.8.4092-4098.2002","article-title":"Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature","volume":"70","author":"Kawahara","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.101_b0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/eji.201141855","article-title":"A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo","volume":"42","author":"Pantel","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0105","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0110","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1016\/j.vaccine.2014.07.015","article-title":"Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant","volume":"32","author":"Dinc","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0115","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2008.09.063","article-title":"Antibodies and cytokines independently protect against pneumonic plague","volume":"26","author":"Kummer","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","article-title":"TNFalpha and IFNgamma contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague","volume":"29","author":"Lin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.101_b0125","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.1073\/pnas.1104588108","article-title":"Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells","volume":"108","author":"MacLeod","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2018.05.101_b0130","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.4049\/jimmunol.1302569","article-title":"TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation","volume":"192","author":"Cui","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0135","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0140","doi-asserted-by":"crossref","first-page":"17997","DOI":"10.1038\/srep17997","article-title":"Energetics of endotoxin recognition in the toll-like receptor 4 innate immune response","volume":"5","author":"Paramo","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.05.101_b0145","doi-asserted-by":"crossref","first-page":"e85838","DOI":"10.1371\/journal.pone.0085838","article-title":"Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide","volume":"9","author":"Han","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.101_b0150","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/js980070s","article-title":"Delivery of MUC1 mucin peptide by Poly(d, l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses","volume":"87","author":"Newman","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2018.05.101_b0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-016-2147-1","article-title":"Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii","volume":"17","author":"Song","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.101_b0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000321826","article-title":"Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I\/IIa study","volume":"154","author":"Pfaar","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.vaccine.2018.05.101_b0165","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1046\/j.1365-2222.2003.01699.x","article-title":"Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies","volume":"33","author":"Mothes","year":"2003","journal-title":"Clin Exp Allergy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T10:37:56Z","timestamp":1568975876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":33,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18307680"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.101","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}